<DOC>
	<DOCNO>NCT01295307</DOCNO>
	<brief_summary>In relapsed refractory AML allogeneic HCT consider treatment long-term disease-free survival achieve . Despite favorable prospect , even young patient relapse AML 40 % patient reach allogeneic HCT . A number factor contribute low rate transplantation , among moderate activity salvage regimens accumulate toxicity prevent transplantation ; Prospective clinical trial indication usually focus either rate CR achieve defined number cycle salvage therapy transplantation modality . The consequent integration salvage therapy transplant strategy account time-dependent process donor search study far . The objective study evaluate safety efficacy clofarabine salvage therapy prior allogeneic HCT .</brief_summary>
	<brief_title>Clofarabine Salvage Therapy Patients With Relapsed Refractory Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>All patient schedule least one cycle induction therapy CLARA . CLARA contain clofarabine 40 mg/m2 ( 1 hr infusion ) day 1-5 follow 3 hour end infusion intermediate dose cytarabine 1 g/m2 ( 2 hr infusion ) day 1-5 . Patients moderate early response ( reduce marrow blast count ≥10 % day 15 ) patient progressive disease delay hematologic recovery ( beyond day 42 ) may receive re-induction therapy similar first cycle induction therapy . Study treatment comprise two cycle induction therapy one two cycle consolidation chemotherapy patient without donor . Consolidation therapy reduce 25 % consist clofarabine 40 mg/m2 ( 1 hr infusion ) day 1-4 follow 3 hour end infusion intermediate dose cytarabine 1 g/m2 ( 2 hr infusion ) day 1-4 . Patients donor identify may proceed allogeneic HCT CLARA I adopt concept allogeneic HCT aplasia . Patients donor search time consume proceed allogeneic HCT donor identify . Patients achieve response last cycle CLARA receive clofarabine part condition regimen . Clofarabine melphalan may give condition therapy patient HLA-compatible donor maximum one mismatch refer HLA-loci A , -B , -C -DRB1 . Conditioning therapy contain clofarabine 30 mg/m2 ( 1 hr IV infusion ) day -6 -3 melphalan 140 mg/m2 ( 1 hour IV infusion ) day -2 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Diagnosis AML accord WHO criterion . Untreated relapse refractory disease minimum one standard induction therapy . Treatment relapse leukocyteapheresis 5 day low dose cytarabine hydroxyurea allow . Refractory disease define ≥5 % blast second cycle induction therapy reduction marrow blast early treatment assessment ( day +15 ) first cycle induction therapy . Relapse define increase bone marrow blast count ≥5 % , reappearance blast peripheral blood extramedullary disease . Age 40 year . Have adequate renal hepatic function indicate follow laboratory value : Serum creatinine &lt; =1.0 mg/dL ; serum creatinine &gt; 1.0 mg/dL , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73 m2 ( see reference below* ) Serum bilirubin &lt; =1.5× upper limit normal ( ULN ) Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) &lt; =2.5× ULN Alkaline phosphatase &lt; =2.5× ULN Eligibility intensive chemotherapy Patient need capable understand clinical trial investigational approach bridge time potential allogeneic HCT , potential risk benefit study . Signed write informed consent . Female patient childbearing potential must negative serum Male female patient must use effective contraceptive method study minimum 6 month study treatment . For refractory disease , two prior induction chemotherapy one prior salvage chemotherapy contain highdose cytarabine ( cumulative dose cytarabine ≥ 5 g/m2 ) . Second high relapse . Patients receive hypomethylating agent like azacytidine decitabine treatment first relapse , respond relapse later may include . Acute promyelocytic leukemia ( 15 ; 17 ) ( q22 ; q12 ) molecular detection ( PML/RARα ) . Central nervous system involvement ( i.e . WBC ≥ 5/µL cerebrospinal fluid blast present cytospin ) . Prior allogeneic HCT Autologous transplantation within 100 day prior start study treatment Use investigational agent anticancer therapy within 10 day study entry exception hydroxyurea lowdose cytarabine . Have severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver , organ system may place patient undue risk undergo transplantation . Patients known refractoriness platelet support . Patients systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Pregnant lactating patient . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>Relapsed refractory AML</keyword>
</DOC>